- Home
- FCO vs ALGS Comparison
FCO vs ALGS Comparison
Compare FCO & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCO | ALGS |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0M | 40.6M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FCO | ALGS |
|---|---|---|
| Price | $2.84 | $7.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | ★ 157.0K | 38.1K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.73 | $4.20 |
| 52 Week High | $6.77 | $13.69 |
Technical Indicators
Market Signals| Indicator | FCO | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 35.04 | 49.41 |
| Support Level | $2.81 | $7.31 |
| Resistance Level | $3.06 | $8.03 |
| Average True Range (ATR) | 0.10 | 0.66 |
| MACD | -0.03 | 0.08 |
| Stochastic Oscillator | 4.42 | 45.63 |
Price Performance
Historical ComparisonAbout FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories: Developed Markets, Investment Grade Developing Markets, and Sub-Investment Grade Developing Markets.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.